| Name | Title | Contact Details |
|---|
Meda is a leading international specialty pharma company with a broad product portfolio reaching more than 80% of the global pharmaceutical market. Sales at the end of 2014 amounted to more than SEK 15 billion (pro forma SEK 18.7 billion). Meda is thereby the 48th largest pharmaceutical company in the world. At the end of 2014 Meda had 5,202 (3,326) employees, 2,996 (2,009) of which worked in sales and marketing. The company’s main focus is sales and marketing and Meda has its own sales organizations in more than 60 countries. Sales and marketing activities are carried out via distributors in countries where Meda has no representation and globally Meda’s products are sold in more than 150 countries.
FloraWorks is a biotech enterprise that specializes in discovering rare and novel cannabinoids for commercial and therapeutic applications. They develop and patent scaled manufacturing pathways for cannabinoids with a high potential for therapeutic use...
Medvantx Pharmacy Services helps pharmaceutical brands do more than just survive in an ever-changing marketplace - we help them thrive in it. Medvantx provides powerful and personalized support to healthcare partners (HCPs) and their patients. We service the specialty needs of pharmaceutical manufacturers by offering patient assistance programs and providing efficient intake solutions, nationwide dispense and fulfillment services, quality aftercare through counseling and customer service, safe and secure data handling, dependable inventory management and logistics, and insightful reporting and accounting. Serving more than 50 pharmaceutical manufacturers and managing more than $7.5 billion B of prescriptions annually, Medvantx has been redefining pharmacy for over 20 years.
Abon Pharmaceuticals is a Northvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.